Literature DB >> 20859325

Brain activity associated with chronic cancer pain.

Asokumar Buvanendran1, Amjad Ali, Travis R Stoub, Jeffrey S Kroin, Kenneth J Tuman.   

Abstract

BACKGROUND: The number of neuroimaging studies that examine chronic pain are relatively small, and it is clear that different chronic pain conditions activate diverse regions of the brain.
OBJECTIVE: Cancer patients presenting for diagnostic positron emission tomography (PET) imaging were asked to rate their spontaneous baseline pain score. Twenty patients with either no pain (NRS = 0) or with moderate to severe pain (NRS = 4) were invited to participate in this study to determine the difference in brain activity in cancer patients with moderate to severe chronic pain versus no pain. STUDY
DESIGN: Prospective, non-randomized, observational report.
SETTING: Academic medical center.
METHODS: Patients had a 2-D PET scan with the radionuclide 18F-fluoro-2-deoxyglucose (FDG) at a dose of approximately 20 mCi. Each individual raw PET scan was coregistered and normalized to standard stereotactic space. Differences in regional glucose metabolism were then statistically compared between patients with moderate-to-severe pain and patients with no pain.
RESULTS: The NRS pain score in the patients with moderate to severe pain (n = 11) was 4.5 [4.0-6.0] (median [interquartile range]) versus 0.0 [0.0-0.0] (p < 0.001) in the group with no pain (n = 9). Compared to patients with no pain, patients with moderate to severe pain had increased glucose metabolism bilaterally in the prefrontal cortex, BA 9-11. Unilateral activation was found in the right parietal precuneus cortex, BA 7. There were no areas of the brain in which there was decreased activity due to moderate to severe pain.
CONCLUSIONS: Our results showing a preferential activation of the prefrontal cortex are consistent with results from studies showing that affective pain perception and negative emotions play an important part in the chronic pain experience. LIMITATIONS: This was not a randomized clinical trial. Patient medication was not controlled.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20859325

Source DB:  PubMed          Journal:  Pain Physician        ISSN: 1533-3159            Impact factor:   4.965


  6 in total

1.  Altered structural covariance and functional connectivity of the insula in patients with Crohn's disease.

Authors:  Shuming Zhang; Fenrong Chen; Jiayu Wu; Chengxiang Liu; Guang Yang; Ruiqing Piao; Bowen Geng; Ke Xu; Peng Liu
Journal:  Quant Imaging Med Surg       Date:  2022-02

2.  Tramadol/paracetamol fixed-dose combination in the treatment of moderate to severe pain.

Authors:  Joseph V Pergolizzi; Mart van de Laar; Richard Langford; Hans-Ulrich Mellinghoff; Ignacio Morón Merchante; Srinivas Nalamachu; Joanne O'Brien; Serge Perrot; Robert B Raffa
Journal:  J Pain Res       Date:  2012-08-29       Impact factor: 3.133

3.  Enhanced GABAergic synaptic transmission at VLPAG neurons and potent modulation by oxycodone in a bone cancer pain model.

Authors:  Keiko Takasu; Koichi Ogawa; Atsushi Nakamura; Tomoe Kanbara; Hiroko Ono; Takako Tomii; Yasuhide Morioka; Minoru Hasegawa; Masahiro Shibasaki; Tomohisa Mori; Tsutomu Suzuki; Gaku Sakaguchi
Journal:  Br J Pharmacol       Date:  2015-02-10       Impact factor: 8.739

4.  Intra and inter: Alterations in functional brain resting-state networks in patients with functional constipation.

Authors:  Dan Zhang; Zai-Long Zhou; Ting Xing; Mei-Yu Zhou; Ye-Ming Wan; Shu-Chen Chang; Ya-Li Wang; Hai-Hua Qian
Journal:  Front Neurosci       Date:  2022-07-22       Impact factor: 5.152

5.  Altered metabolic connectivity between the amygdala and default mode network is related to pain perception in patients with cancer.

Authors:  Wen-Ying Lin; Jen-Chuen Hsieh; Ching-Chu Lu; Yumie Ono
Journal:  Sci Rep       Date:  2022-08-18       Impact factor: 4.996

6.  Central pain processing in chronic chemotherapy-induced peripheral neuropathy: a functional magnetic resonance imaging study.

Authors:  Elaine G Boland; Dinesh Selvarajah; Mike Hunter; Yousef Ezaydi; Solomon Tesfaye; Sam H Ahmedzai; John A Snowden; Iain D Wilkinson
Journal:  PLoS One       Date:  2014-05-12       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.